WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Primary Brain Tumors efficacy endpoints v2, Clinical deterioration ???? Neurologic Signs and Sympotms, Surgical Intervention has type Chemotherapy wafers, perpendicular diameter measured in projection, Sum of the product of all lesions has outcomes -Complete Response (CR) -Partial Response (PR) -Stable disease (SD) -Progression, Enhancing classified as Non-measurable lesions, Qualitative Assessment has attribute - better - same - worse, Mutation determined by Method of mutation detection, Histology provides evidence for Cellular Classification, New lesion identified by Organ specific lesion ID, Objective Response Rate (ORR) derived from C-MET PET F-FET PET, % Staining provides evidence for Intensity score, % Staining instantiated by 1 - 100%, Regional includes Convection enhanced delivery, Immunohistochemistry has Target, Neurologic Signs and Sympotms assessed as - Cognition - HRQoL - Seizure - Functional status, Sum of the product of all lesions includes Total area of each leasion, Enhancing classified as Existing lesion, PRIMARY BRAIN TUMORS (HGG) EFFICACY ENDPOINTS include Overall Survival (OS), Relative Cerebral Blood Volume (rCBV) ???? Regional Tissue Perfusion, Progression free survival (PFS) derived from Quantitative Diffusion-weighted imaging (DWI)